Companies Cryptocurrencies
Autolus Therapeutics PLC
Autolus Therapeutics PLC
Exchange: NasdaqGS
IPO Date: 22/06/2018
CEO: Dr. Christian Martin Itin
Biotechnology Healthcare 🔗
  • AUTL
    symbol
  • 6.14
    price
  • 446639552
    market cap
  • -0.05999994
    changes
If you bought

shares of Autolus Therapeutics PLC (AUTL) on
You would have made
AMOUNT
today.
Old Price $12 Current Price $12

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company’s clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

Address: Scale Space Building White City 58 Wood Lane LONDON W12 7RZ

Stay updated.